AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
Links shared publicly online about this topic.
- 1,656total visits
AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural Sedation, Anxiolysis & Analgesia
AcelRx Pharmaceuticals, Inc. announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazo
View full resource at medicalnewstoday.com
Tags: Pharma, Phase 2 Clinical Trial, Clinical Trial
Most Recently Shared on October 23, 2009 at 12:33 pm By:
AcelRx Announces Positive Results From A Phase 2 Study Of ARX-03, A Sufentanil/Triazolam NanoTab For Procedural.. http://bit.ly/Z2ORl
Advertisement
